- Liz Highleyman | 31 October 2013
Almost all HIV-positive people with undetectable
viral load who switched to once-daily raltegravir (Isentress) maintained viral suppression, French researchers
reported at the 14th European AIDS Conference this month in
Brussels. In an effort ...
- Liz Highleyman | 31 October 2013
Higher baseline viral load, longer time to viral
suppression and low-level viraemia below the level of detection of standard
tests raise the risk of viral rebound amongst people with HIV on antiretroviral
therapy ...
- Liz Highleyman | 30 October 2013
The recently approved HIV integrase inhibitor dolutegravir (Tivicay) provides at least equivalent
antiviral efficacy and better tolerability compared with approved
antiretroviral drugs for treatment-naive people, according to data reported at
the 14th European
AIDS ...
- Liz Highleyman | 29 October 2013
Eighteen per cent of HIV-positive men
acquired hepatitis C virus (HCV) a second time after clearing the virus, with
some having third and fourth infections as well, according to findings from the
European ...
- Gus Cairns | 24 October 2013
Over
Europe as a whole, the proportion of people testing late for HIV decreased
between 2002 and 2010, a presentation at the 14th European AIDS Conference in
Brussels last week showed, and the ...
- Keith Alcorn | 22 October 2013
A switch to a cheaper injectable illicit drug led to a major
outbreak of HIV infection in Tel Aviv, Israel, and should serve as a warning signal for
other cities with apparently ...
- Liz Highleyman | 22 October 2013
HIV
treatment in the coming years will include novel antiretroviral agents and new
formulations such as long-acting injectables, as well as new strategies aimed
at improving adherence and minimising side-effects, it was reported ...
- Liz Highleyman | 22 October 2013
The HCV protease inhibitor faldaprevir added to pegylated interferon and
ribavirin increased the likelihood that HIV/HCV co-infected people would
achieve a sustained virological response at four weeks after completing treatment,
according to a ...
- Gus Cairns | 21 October 2013
A study presented at the 14th European AIDS Conference
last week found that the suicide rate in people with HIV in British Columbia,
Canada, had fallen 35-fold since 1996 and was now ...
- Liz Highleyman | 21 October 2013
Adding the direct-acting
hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported at the 14th European AIDS ...
- Liz Highleyman | 20 October 2013
A dual combination of lopinavir/ritonavir (Kaletra or Aluvia) plus
3TC (lamivudine, Epivir) as
first-line therapy produced good virological suppression regardless of baseline
viral load and was well tolerated in the multinational GARDEL study, ...
- Liz Highleyman | 20 October 2013
The experimental HIV integrase inhibitor GSK1265744 demonstrated rapid and potent antiviral
activity and good tolerability for treatment-naive people in the LATTE study,
according to a report at the 14th European
AIDS Conference this ...
- Keith Alcorn | 19 October 2013
Only 20% of people with HIV in Europe have fully suppressed
viral load, compared to an estimated 24% in sub-Saharan Africa, despite much
higher rates of HIV diagnosis in the European region, ...
- Gus Cairns | 18 October 2013
A new edition of the European
AIDS Clinical Society (EACS) guidelines for the treatment of HIV,
HIV and hepatitis C co-infection, and HIV with other co-morbidities were published in advance of
the 14th ...
- Liz Highleyman | 18 October 2013
The advent of direct-acting antiviral agents can rightly be described as
a revolution in treatment for chronic hepatitis C, but potential challenges
remain – including drug interactions and cost, Heiner Wedemeyer told
participants ...
- Liz Highleyman | 18 October 2013
The dual
CCR5/CCR2 inhibitor cenicriviroc demonstrated good antiviral activity and
tolerability in a phase 2 clinical trial, according to a report at the 14th European AIDS
Conference yesterday in Brussels. The study had ...
- Keith Alcorn | 17 October 2013
The number of people in Europe who have become infected with
a drug-resistant strain of HIV may have increased by around 35% since 2003, even though
the total prevalence of drug resistance ...
- Keith Alcorn | 17 October 2013
Women living with HIV had a higher risk of anal
pre-cancerous changes than cervical changes linked to human papillomavirus (HPV),
French researchers reported at the 14th European AIDS Conference in
Brussels. They suggested ...
- Liz Highleyman | 17 October 2013
Is a functional cure for HIV feasible within the foreseeable future or
is it a hopeless quest robbing resources from more practical approaches to
improve the lives of people living with HIV? ...
- Liz Highleyman | 17 October 2013
The first day of the
14th European AIDS Conference, which opened yesterday in Brussels, featured a
satellite symposium on development of HIV microbicides, broadly defined to
include a variety of approaches to pre-exposure ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...